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PRADl (Cyclin Dl): A Parathyroid Neoplasia Gene on llql3

Andrew Arnold,* Torn Motokura,* Theodora Bloom,^ Carol Rosenberg,* Allen Bale,*
Henry Kronenberg,* Joan Ruderman,^ Milton Brown,* and Hyung Goo Kim*

Hyperparathyroidism is a central component of multiple endocrine neoplasia type I (MEN 1), and
both sporadic and familial forms ofparathyroid disease may share certain pathogenetic features. We
recently identified a gene that is clonally rearranged with the PTH locus in a subset of sporadic
parathyroid adenomas. This candidate oncogene, PRADl (previously Dl 1S287), appears to contribute to parathyroid tumorigenesis in a fashion analogous to activation of C-MYC or BCL-2 by
rearrangement with tissue-specific enhancers ofthe immunoglobulin genes in B-lymphoid neoplasia.
The PRADl gene maps to I lqI3 and has been linked to the BCL-l breakpoint locus, although not to
the most tightly linked MEN I markers, by pulsedfield gel electrophoresis. PRADl may. in fact, be the
long-sought BCL-l lymphoma oncogene. PRADl encodes a novel type of cyclin protein and thus may
normally function in controlling the cell cycle, perhaps through direct interaction with cdc2 or a
related kinase. PRADl s possible primary, or more likely secondary, involvement in the pathogenesis
of MEN 1-related tumors is unknown and under investigation. (Henry Ford Hosp Med J 1992:40:17780)

H

yperparathyroidism is a central component of familial
multiple endocrine neoplasia type 1 (MEN 1), Our recent
identification of a cellular oncogene that appears to participate
in the pathogenesis of a subset of nonfamilial or sporadic parathyroid adenomas could be relevant in MEN 1, since familial
and sporadic forms of other types of tumors can share pathogenetic features. We provide a brief review of the characterization
ofthis gene. PRADl (or cyclin Dl).
During studies that established the monoclonality of parathyroid adenomas, we encountered two tumors with parathyroid
hormone (PTH) gene rearrangements (1). Molecular dissection
showed that in one case the tumor-specific clonal rearrangement
.separated the PTH gene's 5'fiankingregion from its coding exons in a reciprocal recombination event (2). Because the allelic
rearrangement appeared to be present in every cell of the tumor,
and thus was apparently present in the tumor's original clonal
precursor, it was likely to be pathogenetically relevant. One possibility was that the PTH gene's regulatory elements, which actively up-regulate PTH transcription in parathyroid tissue, were
infiuencing the expression of a proto-oncogene that was placed
in this vicinity by the rearrangement. Such a situation would be
analogous to the juxtaposition of immunoglobulin sequences
with the C-MYC or BCL-2 oncogenes in Burkitt's lymphoma or
follicular lymphoma, respectively (3-5); in both examples the
tissue-specific enhancer is "tricked" by the DNA rearrangement
into activating transcription of the misplaced proto-oncogene.
The DNA of unknown origin that had been rearranged with
the PTH locus was cloned and found to be normally located on
chromosome 11; it was initially called D l 1S287 (2). In situ hybridization more precisely localized D11S287 to band l l q l 3
(2). This localization was intriguing in that 11 q 13 was the established location of the known or suspected oncogenes INT-2,
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HST-1, SEA, and BCL-1, as well as the MEN 1 gene, a still unidentified putative tumor suppressor. The cloned D l 1S287 sequences, however, did not appear to include the INT-2, HST-1,
SEA, or BCL-l loci, based on restriction map comparisons and
DNA hybridization data. Because the PTH gene is located on
the short arm of chromosome 11 (1 lpl5), the simplest cytogenetic explanation for the observed molecular rearrangement is a
pericentromeric inversion; however, direct cytogenetic information could not be obtained on the frozen tumor specimen.
Subsequent study of a panel of tumors at our in.stitution and at
another revealed two additional and completely independent
parathyroid adenomas with similar PTH/Dl 1S287 DNA rearrangements (6,7). In both cases, the breakpoints within the PTH
gene are similar to that in the original tumor. Regarding the
l l q l 3 breakpoints, one was approximately 15 kb from that in
the first tumor (6) (Fig 1), while the other was similar to the original breakpoint in this respect (7).
Next, we showed that a subclone of D11S287 contained a
transcribed sequence, detectable on blots of parathyroid RNA;
this expressed sequence was called D11S287E and, later,
PRADl, for parathyroid adenomatosis-1. The normal size
PRADl mRNA was overexpressed about 15-fold in all parathyroid tumors bearing the clonal PTH/PRAD1 region DNA rearrangements (6). This impressive tumor-specific transcriptional
activation associated with a clonal DNA rearrangement further
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Fig I—A) Schematic representation of PTH-Dl 1S287 rearrangements in two parathyroid adenomas (2,6). The 5' PTH region (IlpIS, thick lines) was juxtaposed to the Dl IS287 region
(llql3, thin lines). The breakpoints (X) in the DIIS287 region
are 15 kh apart. B) Genomic probe B (2) is shown as a darkened
box, whose open area represents the first e.xon of PRADl. C)
Restriction maps ofthe inserts of three representative overlapping PRADl cDNA clones, 'kPl-4, XPI-5. and XP2-3. D) Deduced restriction map ofthe PRADl cDNA. The coding region
is shown as a crosshatched box. Scale of 1 kilobase is shown as
arrows. Symbols used for restriction sites are B, BamHI; R,
EcoRI; H, Hindlll; P, Pstl. (Reprinted hy permission from Nature, Vol 350, pp. 512-5. Copyright © 1991, Macmillan Magazines, Ltd.)

supported the hypothesis that PRADl was likely a proto-oncogene.
Additional studies have intensified interest in PRADl as a
candidate oncogene. It has been known for a few years that 15%
to 20% of human breast cancers and squamous cell cancers of
the head and neck contain DNA amplification of a part of 1 Iql 3
that usually includes INT-2, HST-1, and the BCL-l breakpoint
locus, as reviewed by Lammie et al (8). However, none of these
loci is invariably present on the amplicon, and none is regularly
expressed in this subset of tumors. Therefore, it has been assumed that at least one additional oncogene, more central to the
pathogenesis of these tumors, lies in this vicinity. PRADl is an
excellent candidate for being such an oncogene, because it was
recently shown to be consistently present on the 1 lql3 amplicon in this subset of breast and squamous cell cancers and, importantiy, was also expressed in the tumors (8).
PRADl also appears to be a key B-cell lymphoma oncogene.
Some B-cell tumors contain a translocation involving the immunoglobulin heavy chain locus (14q32) with a region on
l l q l 3 . The DNA on l l q l 3 adjacent to the breakpoint was
cloned and named BCLl with the expectation that a new oncogene would be found in this DNA and would be deregulated by
the rearrangement (9). For years, extensive searching of the
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DNA adjacent to the original BCLl breakpoint locus failed to
reveal a transcribed gene (10,11). Recent data suggest that
PRADl may be the elusive "BCLl oncogene" because the
BCLl breakpoint locus is closely linked to PRADl (8,12-14),
because PRADl appears to be consistently overexpressed in
centrocytic lymphomas (a subtype characterized by frequent
BCL-l rearrangements) (13), and because no other CpG island
lies within the 120 kb between the BCL-l breakpoint and
PRADl (13,14). Thus, with PRADl being implicated as a putative oncogene in several tumor types, it was of great interest to
identify its normal stmcture.
We screened a human placental cDNA library with Dl 1S287/
PRADl genomic probe "B" (Fig 1), already known to contain
transcribed sequences (6). We obtained overlapping cDNA
clones that included the full 4.5 kb expected length (Fig 1C and
ID). PRADl cDNA (EMBL Accession #X59798) encodes a
295 amino acid protein without close homology to any previously reported protein, but with a consistent, weaker relationship (Fig 2) to the cyclin A and B families (29% to 34% identity)
and yeast CLNs or Gl cyclins (19% to 20% identity) (15). Certain stmctural features raise the question of whether or not
PRAD 1 might be a human "G1 cyclin" or yeast CLN equivalent,
controlling the important transition from Gl into S phase of the
cell cycle. Interestingly, investigators .searching for human G1
cyclins by rescue of yeast CLN mutants have recently reported
isolating the PRADl cDNA, now often termed cyclin D l (16,
17). Since cyclins A and B, known to function in the S or G2/M
phases, can also rescue these mutants, these data do not in themselves convincingly prove that PRADl/cyclin D l normally
functions as a G1 cyclin. In further support ofthis role, however,
the mouse homologue of PRAD 1 was identified in a search for
genes that were induced in Gl by colony-stimulating factor 1
(CSF-1) in macrophages (18). Whatever its function is ultimately determined to be, PRAD I's sequence similarities with
all known cyclins and the inability to readily assign it to an existing family indicate that PRAD 1 represents a new cyclin famdy.
PRADl mRNA is expressed in multiple normal tissues, including parathyroid, thyroid, placenta, lymph node, skeletal
muscle, heart, liver, and breast (15). Northem blots indicate that
its mRNA is also highly conserved across species from human
to mouse (15). The amino acid sequence of the mouse homologue of PRADl is 94% identical to the human sequence (18).
PRADl may also be part of a multigene family in the human
genome as it is in the mouse; distinct cDNA clones are detectable by hybridization at reduced stringency, and we have observed additional bands that hybridize with the PRADl cDNA
probe on genomic Southem blots washed at decreased stringency.
PRADl protein was purified after expression in bacteria and
added to a clam embryo interphase lysate which lacks endogenous cyclins A and B and contains inactive cdc2 kinase
(19). Subsequentiy, the PRADl protein could be isolated using
pj3suci (a reagent that avidly binds cdc2-like molecules), implying but certainly not proving that PRADl had been complexed
with cdc2 kinase or a related kinase which was directly bound
by pH^"*^' (15). Addition of PRADl protein to the same lysate
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Fig 2—Sequence homology in the "cyclin box" region betH'een the predicted PRADl protein and A-type cyclins (human and clam
cyclin A, 32.2% and33.6% identity, 56.6% and59.2% similarity), B-type cyclins (human cyclin B and Saccharomyces pombe cdc7i,
29.6% and31.6% identity, 50% and 52% similarity), and one S. cerevisiae Gl cyclin (clni, 19.1% identity, 44.1% similarity). Clam
cyclin A and S. pombe cdc/i homologies with PRADl are representative of those found in their families; cln3 is better aligned with
PRADl than is cin/ or 2. I - identical amino acids; * = conservative substitutions. Alignment was made with the assistance of the
BESTFIT program and conservative amino acids are grouped asfollows; D, E, N, Q; H, K, R; A, G, P. S, T; I, L, M, V; F, W, Y.
Amino acid numbers are on the right. (Reprinted hy permission from Nature, Vol 350,pp. 512-5. Copyi'ight © 1991, Macmillan Magazines, Ltd.]

induced phosphorylation of histone H I , a favored substrate for
cdc2 kinase (15). These preliminary observations support the
view that PRAD 1 is indeed a new cyclin, both stmcturally and
functionally, but multiple possibilities regarding its tme physiologic role remain.
To summarize, therefore, PRADl is a gene that has been
strongly implicated in the pathogenesis of subsets of parathyroid, B-lymphoid, breast, and epidermoid tumors, apparently as
a direct-acting oncogene activated by clonal rearrangement or
amplification. PRADl encodes a novel cyclin, whose normal
function, presumably in cell cycle control, remains unclear at
this early stage of investigation, but may well be important in
the crucial Gl-S phase transition that commits a cell to divide.
Despite PRAD I's location in the genome at 1 Iql 3 and its role in
sporadic parathyroid neoplasia, it seems unlikely that PRADl is
the major predisposing gene for MEN 1. First, the 1 Iql3 markers most closely linked to MEN 1 are centromeric to the BCL-l/
PRADl region, probably by a few megabases (20). Second,
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PRAD I's involvement in neoplasia appears to occur in the context of overexpression of the normal gene product due to chromosome rearrangement or amplification, and thus as a directacting oncogene, while the still uncloned MEN 1 gene is likely
to be a tumor suppressor, participating in neoplasia through its
loss of function.
Nonetheless, PRAD 1 could stdl play an important role in the
parathyroid tumors (and possibly other tumors) in the MEN 1 or
even MEN 2 syndromes. Such a potential role could be envisioned to involve a somatic DNA change (genetic "hit") that
contributes to tumor development in a secondary fashion (i.e.,
beyond the required lesion in the MEN 1 gene itself). In this regard, the issue of whether PRADl's location at 1 Iql3 is simply
a coincidence or whether some 11 q 13 deletional rearrangements
might activate PRADl in the process of deleting the MEN 1
gene needs to be explored.
The precise mechanisms by which deregulated expression of
PRADl is related to tumor development are unknown. It is even
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possible that some of its sites of action in neoplasia could be
qualitatively different from those involved in its normal function and therefore much study will be required. Such study is
likely to strengthen our knowledge of the links between the cell
cycle control apparatus and oncogenic processes in parathyroid
and othertissuesand could well have implications for illuminating fully the pathogenetic mechanisms in familial endocrine
neoplasia syndromes.
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